GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Cash Receipts from Operating Activities

Bausch & Lomb (TSX:BLCO) Cash Receipts from Operating Activities


View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Cash Receipts from Operating Activities?

Cash Receipts from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.

Bausch & Lomb (TSX:BLCO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Cash Receipts from Operating Activities
Comparable Companies
TSX:OPS TSXV:ZEN TSXV:OTC XCNQ:TEVO ISRG XPAR:EL BDX TSE:7741 XSWX:ALC WST OCSE:COLO B RMD TSE:4543 XSWX:STMN XPAR:DIM BAX TSE:7733 HOLX COO TSE:6869
Traded in Other Exchanges
BLCO:USA S2L:Germany
Address
520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Website
https://www.bausch.com
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.